Development of Nanoparticle Formulations of Cisplatin for Treatment of Triple Negative Breast Cancer by Tyson, Rachel
 
 
 
Development of Nanoparticle Formulations of Cisplatin 
for Treatment of Triple Negative Breast Cancer 
 
 
 
 
Rachel J. Tyson 
PharmD Candidate 2018 
 Author: 
 
 
_____________________________ 
 
 
 
  
Dr. William C. Zamboni, PharmD, PhD 
Associate Professor, UNC Eshelman School of Pharmacy 
Director, Translational Oncology and Drug Development Initiative Lab 
 Advisor: 
 
 
_____________________________ 
 
 
 
 
 
 
 
 
 
 
 
Honors Manuscript 
UNC Eshelman School of Pharmacy 
University of North Carolina at Chapel Hill 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
March 1, 2018 
  
Introduction 
 
Breast cancer is the second leading cause of cancer-related death of women in the United 
States, and triple negative breast cancer (TNBC) is responsible for up to 17% of all breast cancers. 
TNBC is a subtype of breast cancer defined by lack of estrogen receptors, progesterone receptors, 
and HER2 on the tumor cell surface. This type of cancer is both aggressive and difficult to target 
therapeutically. TNBC is characterized by high rates of metastatic disease and patients diagnosed 
with TNBC have a poor prognosis.(1,2,3) Chemotherapy remains the cornerstone of treatment in this 
type of cancer, and preclinical evidence suggests that platinum based therapy may be especially 
useful in TNBC.(4) Unfortunately, while chemotherapy utilizing small molecule drugs can be helpful in 
treating cancer, it also leads to toxicity throughout the body. Therapy developed to provide improved 
delivery of therapy in difficult to treat cancers could boost efficacy (anti-tumor effects) while reducing 
toxicity (off-target effects). In the case of TNBC, there are currently no proven efficacious targeted 
therapies available, and the only accepted strategy for recurrent or metastatic disease is to 
‘rechallenge’ with systemic chemotherapy.(1) Therefore, new treatment modalities are urgently 
needed to manage TNBC and ultimately provide better outcomes for patients.  
Nanoparticle based drug formulations have significant benefits over traditional small molecule 
agents. By using nanoparticles, we can improve the solubility of hydrophobic drugs, prolong the half-
life of drug circulation in the blood, release drugs at a sustained rate, and deliver multiple drugs 
simultaneously for combination therapy.(5) The development of nano formulations has opened many 
doors for providing customizable and safer treatment options in challenging diseases, including 
cancer. Nanoparticles vary in size but generally range from 100 to 500 nanometers. Through the 
manipulation of size, surface characteristics, and components, nanoparticles can be engineered into 
successful drug delivery systems.  
Nanoparticle agents can deliver drug to specific tissues, such as tumor, and provide controlled 
release therapy. This targeted and sustained drug delivery decreases drug related toxicity and can 
increase patient compliance due to less frequent dosing. Nanoparticle based therapy has the ability to 
increase delivery to tumors by either passive or active targeting.(6) Passively targeted agents, which 
are predominant on the market, use the enhanced permeability and retention (EPR) effect of the 
tumor microenvironment. Active targeting can be achieved by the addition of tumor cell specific 
ligands to the nanoparticle surface. For example, targets for TNBC include the EGFR and HER3 
receptors, both of which are overexpressed on the surface of TNBC cells.(1) The targeting of tumor 
cells either by passive or active means can help deposit drug in the area of the tumor, rather than in 
normal cells around the body. However, insufficient tumor penetration remains a major obstacle to 
delivery of nanoparticle drug carriers.(7,8) 
Particle factors such as size and shape are essential to achieving appropriate tumor 
penetration and distribution.(9) Nanoparticles smaller than 100 nanometers are regarded as most 
promising for extended circulation in the blood as well as tumor penetration.(10) While particle size is 
considered to be the predominant factor in determining circulation time and distribution in the body, 
other factors such as mechanical flexibility of nanoparticles may be very important as well. Several 
studies have emphasized the role of high deformability (‘softness’) in extending circulation time and 
tumor cell uptake.(11,12) Based on these studies, nanoparticles with a high amount of softness could 
have the advantage of greater mobility in confined areas (such as pores in tumor vasculature) and 
therefore may have a better ability to navigate into the tumor.  
A new type of nanoparticle under study has been engineered to be a versatile and targetable 
drug carrier for use in cancer treatment.(13) These nanoparticles (which will be the focus of this paper) 
exhibit very low adhesion to non-targeted surfaces, which may reduce off-target side effects during 
delivery to tumors.(14) They are also able to incorporate both water-soluble and water-insoluble drugs 
within their core.(15,16) Thus, this type of nanoparticle can potentially modify the pharmacokinetics 
(PK), biodistribution, safety and efficacy of anti-cancer therapeutics by providing prolonged blood 
circulation and increased tumor accumulation.(17) Notably, these nanoparticle agents are “soft”, 
compared to PEGylated liposomes, and can possess a broad range of chemical properties.(14) Details 
of the nanoparticle formulation are confidential and thus general terms will used to describe and 
identify the nanoparticle agent throughout the remainder of the manuscript. 
Genetically engineered mouse models (GEMM) are valuable experimental models for 
discovery of biomarkers and prediction of chemotherapy responses in human cancers. GEMMs of 
interest in the study of TNBC include basal-like (C3-TAg) and claudin-low (T11), both of which 
recapitulate the human breast cancer phenotype. C3-TAg subtype is characterized by high 
expression of basal gene expression features. Claudin-low (T11) tumors, while also being TNBC, 
have a smaller response to anthracycline/taxane based chemotherapy. Therefore, patients with T11 
type tumors are more refractory to chemotherapy, with worse prognosis.(18) The T11 model, which 
has been characterized extensively at UNC, was used in this study however ultimately the C3-TAg 
subtype will be used as well.  
Based on the unique properties of the nanoparticles under study, their use as a drug delivery 
system should allow for longer circulation as well as greater accumulation of cisplatin in tumor tissue 
as opposed to small molecule cisplatin alone. The aim of the current study is to compare the in vivo 
PK and tumor distribution of small molecule cisplatin with nanoparticle formulations of cisplatin in 
murine GEMMs of TNBC. The study also aims to compare PK differences between different levels in 
drug loading (i.e. ‘Low Load and ‘High Load’) nanoparticles. The results of this study will provide 
insight about the passive delivery of cisplatin-loaded nanoparticles in a TNBC model and guide the 
direction of future studies with combination therapy and targeted nanoparticle therapies. 
 
Methods 
 
Nanoparticles, termed ‘Low Load’ and ‘High Load’, were provided to our group by Dr. Tatiana Bronich 
from the University of Nebraska Medical Center. All nanoparticles were received in water and 
protected from light during shipment and storage. The difference in ‘Low Load’ and ‘High Load’ is 
based on the concentration of cisplatin within each micelle: an estimated average of 5.6 particles of 
‘low load’ gives the cisplatin concentration equivalent to one ‘high load’ particle (Table 1). A sample 
from each stock of the nanoparticles received was diluted and measured to confirm concentration by 
inductively coupled plasma mass spectrometer (ICP-MS) before animal administration.  
 
After confirmation of dosing solution concentrations, the nanoparticle agent was diluted with 50% 
dextrose to achieve a 5% dextrose solution (D5W) in order to be appropriate for injection into mice for 
PK studies, no more than 24 hours before administration. Dosing of the ‘High Load’ was based on 
maximum tolerated dose (MTD; roughly 4 mg/kg) studies in non-tumor bearing BALB/c mice. Dosing 
of the ‘Low Load’ was based on the maximum deliverable dose (MDD; roughly 1.1 mg/kg) of ‘Low 
Load’ nanoparticles received. Table 1 shows a summary of the dosing solution dilution and 
components. In addition to nanoparticle dosing solutions, small molecule cisplatin was also prepared 
for administration into mice, to serve as a comparison to the nanoparticles. 
 
In vivo experiments were performed with the approval of the University of North Carolina at Chapel 
Hill’s Institutional Animal Care and Use Committee (IACUC). T11 GEMMs were orthotopically 
transplanted into the lower mammary fat pad of female BALB/c mice by the Mouse Phase I Unit 
(MP1U) within the UNC Lineberger Comprehensive Cancer Center. Transplanted mice were then 
cared for following DLAM guidelines by the Animal Studies Core (ASC).  
 
Table 2 summarizes the study design of the PK studies performed. Small molecule cisplatin and 
cisplatin-loaded nanoparticles were administered at 1.1 mg/kg or 4.0 mg/kg IV x 1 via a tail vein, as 
summarized in Table 2. Mice (n=3 per time point) were euthanized prior to and at 0.083, 0.5, 1, 6, 24, 
and 96 hours after administration of each drug. Blood was collected via cardiac puncture in sodium 
heparin, before processed into plasma and stored at -80°C until processing. Tissues for analysis were 
flash frozen after collection and stored at -80°C until processing. 
 
Plasma and tissues were hydrolyzed in 70% nitric acid containing 200 ng/mL Iridium internal 
standard. Samples were incubated at 100°C for 90 minutes before adding water to dilute the sample 
to 2.5% nitric acid final concentration. Samples were centrifuged at 3,000 x g for 5 minutes and 
decanted to remove particulate and bulk material. The samples were then analyzed by ICP-MS. 
Noncompartmental PK analyses of the nanoparticle formulations of cisplatin and small molecule 
cisplatin in plasma, tumor, and tissues were performed using Phoenix WinNonLin v8.0 (Certara, L.P.). 
The area under the concentration versus time curve was calculated using the linear up and log down 
rule.  
 
Results 
 
Results from plasma and each tissue are presented in Figure 1, and PK values including clearance, 
volume of distribution, and AUC for plasma and each tissue are displayed in Table 3. PK values are 
derived from the average concentration values of three mice at each time point.  
 
Plasma 
 
The plasma PK demonstrated greater cisplatin exposure in nanoparticle formulations of cisplatin 
compared to small molecule cisplatin. Compared to small molecule cisplatin, both ‘Low Load’ and 
‘High Load’ nanoparticle formulations displayed higher dose-normalized AUC when administered at 
1.1 mg/kg (3,544.6 h*ng/mL versus 5,864.8 & 8,524.9 h*ng/mL, respectively) and 4 mg/kg (1,826.2 
versus 11,049.8 h*ng/mL, respectively). However, the increased total platinum exposure between 
‘Low Load’ and ‘High Load’ nanoparticles administered at 1.1 mg/kg were similar (1.7 and 2.4-fold 
increase, respectively). Differences in plasma platinum AUCs between nanoparticles and small 
molecule cisplatin were driven by greater exposure/slower clearance of nanoparticle formulations up 
to 24 hours post-administration. This is represented by both the clearance and AUC data calculated 
in plasma. Platinum concentrations were higher with small molecule cisplatin compared to the three  
nanoparticle doses at 96 hours. ‘Low Load’ nanoparticles were below the limit of quantitation at 96 
hours. Additional studies at MTD (i.e. 4 mg/kg) will be needed to determine if ‘High Load’ 
nanoparticles continue to demonstrate an improved exposure profile compared to ‘Low Load’ 
counterparts. 
 
Tumor 
 
Tumor PK data showed roughly 2 to 4-fold greater total platinum exposure with nanoparticle 
formulations of cisplatin compared to cisplatin alone when administered at lower doses (i.e. 1.1 
mg/kg), and up to 6-fold greater exposures at MTD (i.e. 4 mg/kg). Both ‘Low Load’ and ‘High Load’ 
nanoparticle formulations displayed higher dose-normalized AUC than cisplatin when administered at 
1.1 mg/kg (10,6112.0 h*ng/mL versus 21,194.8 & 33,532.6 h*ng/mL, respectively) and 4 mg/kg 
(6,100.0 versus 38,882.4 h*ng/mL, respectively). ‘High Load’ nanoparticle formulations displayed 
similar tumor platinum concentrations regardless of dose. There is also a potential distribution 
difference up to 24 hours post-administration. Small molecule cisplatin and ‘Low Load’ nanoparticles 
exhibited about 5-fold lower concentration before the 24 hour time point. However, after 24 hours 
post-administration, ‘Low Load’ nanoparticle tumor platinum concentrations were similar to ‘High 
Load’ nanoparticles.  
 
Liver & Spleen 
 
Liver and spleen PK demonstrated similar trends. Dose-normalized liver PK was shown to be 7 to 10-
fold greater with nanoparticle formulations of cisplatin (214,985.9, 301,095.1, and 275,462.5 h*ng/mL) 
compared to small molecule cisplatin (29,041.2 and 19,721.3 h*ng/mL). Nanoparticle formulations 
displayed similar liver platinum concentrations regardless of 1.1 mg/kg or 4.0 mg/kg dose (301,095.1 
versus 275,462.5 h*ng/mL, respectively for ‘High Load’ nanoparticles). The 1.1 mg/kg ‘Low Load’ 
nanoparticle liver platinum concentrations before 24 hours post-administration were about 2 to 3-fold 
lower than 1.1mg/kg ‘High Load’ nanoparticles, but attained similar concentration levels after 24 
hours. 
 
Dose-normalized spleen PK was 7 to 11-fold greater with nanoparticle formulations of cisplatin 
(94,295.1, 148,697.5, and 141,820.8 h*ng/mL) compared to cisplatin alone (12,290.0 and 8,190.7 
h*ng/mL). Nanoparticle formulations displayed similarly increased spleen platinum exposure 
regardless of dose. ‘Low Load’ nanoparticle tumor platinum concentrations before 24 hours post-
administration were about 2-fold lower than ‘High Load’ nanoparticles, a finding that is less 
pronounced after 24 hours.  
 
Liver and spleen nanoparticle PK showed very similar increased exposure compared to small 
molecule cisplatin. Liver and spleen exposures are both greater after ‘High Load’ nanoparticles 
compared to ‘Low Load’ nanoparticles.   
 
Muscle 
 
Dose-normalized muscle PK was 2 to 3-fold higher with small molecule cisplatin compared to the 
nanoparticle formulations. Plasma platinum concentrations were higher with cisplatin alone compared 
to any of the other three nanoparticle doses after 6 hours post-administration. ‘Low Load’ nanoparticle 
formulations displayed lower dose-normalized AUC than cisplatin when administered at 1.1 mg/kg 
(4,751.1 h*ng/mL cisplatin versus 1,592.5 h*ng/mL ‘Low Load’ nanoparticles). Additionally, it was 
observed that small molecule cisplatin at 4.0 mg/kg provided similar exposure to ‘High Load’ 
nanoparticles at 4.0 mg/kg (3,210.6 versus 3,447.0 h*ng/mL, respectively). 
 
When comparing differences between muscle and tumor, it was found that nanoparticle formulations 
of cisplatin achieve higher exposure in tumor versus muscles; whereas the results are opposite for 
small molecule cisplatin. Muscle exposure is lower with nanoparticle formulations compared to small 
molecule cisplatin. Tumor and muscle exposures are each greater for ‘High Load’ nanoparticles 
compared to ‘Low Load’ nanoparticles in the first 24 hours. The difference in muscle exposure for 
‘Low Load’ nanoparticles may be driven by an abbreviated AUC due to samples falling BLQ at 96 
hours post-administration. 
 
Discussion 
 
These data from the PK studies provide insight for how nanoparticles of different types (‘Low Load’ 
and ‘High Load’) compare to one another in terms of distribution and clearance, as well as how these 
compare to small molecule cisplatin. In terms of the comparison between small molecule cisplatin and 
nanoparticle formulations of cisplatin, it was found that the nanoparticles had higher PK exposures 
than cisplatin in plasma, liver, spleen, and tumor. The plasma results may be explained by slower 
nanoparticle clearance, resulting in a longer time for the nanoparticles to be exposed to the plasma. 
However, these PK differences were only observed up to 24 hours post-administration. The similar 
concentrations of cisplatin and nanoparticle formulations of cisplatin after the 24-hour time point could 
potentially be due to the degradation of the nanoparticle. Loss of the nanoparticle’s original formation 
could have lead to the release of cisplatin into blood and tissues and caused the results observed. 
However, further study is needed to fully understand the fate of this type of nanoparticle carrier in 
vivo. In addition, future studies need to evaluate the exposure of protein unbound platinum in plasma 
after administration of all agents and especially after administration of cisplatin as most of the 
measured platinum in plasma is likely protein-bound platinum, which is inactive. Additionally, analysis 
of plasma ultrafiltrate will allow investigations of formulation driven differences in non-protein bound 
platinum (i.e. free/released platinum). Information on percentage of non-protein bound platinum 
compared to total platinum may help explain potential benefits and variations between small molecule 
cisplatin and nanoparticle formulations. As only non-protein bound drug is able to permeate into 
tumor, the free platinum fraction is important factor in treatment efficacy.  
 
The increased accumulation of nanoparticle formulations of cisplatin compared to small molecule 
cisplatin in the liver and spleen could be explained due to increased mononuclear phagocyte system 
(MPS) uptake of the nanoparticles. The MPS plays a role in clearing drug from the body and 
comprises a family of cells including bone marrow progenitors, monocytes, and macrophages, all 
which uptake particles.(19) Less liver and spleen accumulation for ‘Low Load’ could be due to ‘Low 
Load’ particles saturating the MPS more quickly than the ‘High Load’.  
 
Finally, nanoparticle accumulation in tumor could be explained by the EPR effect. Based on the EPR 
effect, particles in the size range of nanoparticles will be taken up by tumors. In contrast, nanoparticle 
PK showed decreased exposure compared to small molecule cisplatin in muscle. This is likely due to 
the fact that small molecule drugs are able to extravasate into muscle, while the larger nanoparticles 
may not. These results are expected based on what is currently known about small molecules and 
nanoparticles.  
 
In terms of comparison between ‘Low Load and ‘High Load’ nanoparticle formulations of cisplatin, the 
data is less clear as to potential benefits. It was found that there was not a four-fold increase as 
expected in the ‘High Load’ nanoparticles compared to the ‘Low Load’. This non-linearity could be 
due to the unique properties (such as ‘softness’) of these nanoparticles. Also noted was that ‘High 
Load’ nanoparticles had higher PK exposures compared to ‘Low Load’ nanoparticles in plasma, 
tumor, and tissues within the first 24 hours of administration. ‘Low Load’ nanoparticles could possibly 
be less stable in the blood and more quickly metabolized. Additionally, particle number may play a 
major role in differences seen between ‘Low Load’ and ‘High Load’. Other nanoparticles such as 
Particle Replication in Non-wetting Templates (PRINT) particles display superior tumor delivery with 
lower amounts of drug loaded within the particles. Because more (lower loaded) particles are needed 
to deliver drug, the increased number of particles saturates the MPS of the liver and spleen. 
Therefore, rather than the drug being quickly cleared by the MPS, the saturation effect caused by the 
lower loaded particles allows for increased exposure to plasma and tumor.(20) Based on this 
information, one would expect the ‘Low Load’ nanoparticle formulations of cisplatin to show increased 
plasma and tumor exposure as compared to the ‘High Load’. However, this type of nanoparticle 
formulation may have different properties than nanoparticles such as the PRINT particles, leading to 
the unexpected results observed between the ‘Low Load’ and the ‘High Load’. Further studies are 
needed before conclusions can be drawn regarding the influence of particle number on PK. To clarify 
these findings, MTD studies for both ‘Low Load’ and ‘High Load’ will need to be performed. More 
profound differences may be observed once each formulation is prepared at 4 mg/kg for MTD 
studies. 	
 
Overall, although a limited amount of information is currently available on these nanoparticle 
formulations of cisplatin, they represent a promising method for increasing the delivery of lifesaving 
drugs for the treatment of solid tumors.  
 
 
 
 
 
Table 1. Dosing Solutions of Nanoparticle Formulations of Cisplatin for PK 
Studies in a T11 GEMM 
Nanoparticle Dosing Solution Lower Concentration 
 ‘Low Load’: 0.125 mg/mL  
cisplatin in water 
‘High Load’: 0.70 mg/mL  
cisplatin in water 
 ~5.6 particles of low load gives a cisplatin 
concentration delivered by ~1 high load 
  
~1 particle of high load gives a cisplatin 
concentration equivalent to ~5.6 low 
load particles 
Stock 228 µL of 0.125 mg/mL 40.7 µL of 0.70 mg/mL 
D50W 12.5 µL 12.5 µL 
H20 9.5 µL 196.8 µL 
= 250 µL of 0.114 mg/mL 250 µL of 0.114 mg/mL 
Nanoparticle Dosing Solution Higher Concentration 
 ‘High Load’: 0.70 mg/mL cisplatin in water 
Stock 142.9 µL of 0.70 mg/mL 
D50W 12.5 µL 
H20 94.6 µL 
= 250 µL of 0.40 mg/mL 
 
 
 
Table 2. Study Design for Nanoparticle Formulations of Cisplatin PK 
Studies in a T11 GEMM Mouse Model 
Mouse model T11 GEMM of breast cancer (Balb/c injected) 
Number of mice per time 
point 
N = 3 
Number of doses per 
mouse 
Single dose (IV x 1) 
Treatment arms & doses 1) Cisplatin at 1.1 mg/kg 
2) ‘Low Load’ nanoparticle formulation of cisplatin at 1.1 mg/kg 
3) ‘High Load’ nanoparticle formulation of cisplatin at 1.1 mg/kg 
4) ‘High Load’ nanoparticle formulation of cisplatin at 4.0 mg/kg 
5) Cisplatin at 4.0 mg/kg 
Time points Pre, 5 min, 1 hr, 6 hr, 24 hr, 96 hr 
Tissues analyzed 
		
	 
Blood/Plasma Spleen 
Tumor Muscle 
Liver  
Analytical Measure total platinum in plasma, tumor, and tissues 
 
(Total platinum = protein bound +unbound platinum) 
Figure 1. Concentration versus time plots of total platinum in plasma, tumor, and tissues 
displaying PK differences between small molecule cisplatin, ‘Low Load’ cisplatin-loaded 
nanoparticles, and ‘High Load’ cisplatin-loaded nanoparticles.
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Estimated Total Platinum PK Parameters in plasma, tumor, and tissues displaying 
differences between small molecule cisplatin, ‘Low Load’ cisplatin-loaded nanoparticles, and 
‘High Load’ cisplatin-loaded nanoparticles. 
Treatment 
t
1/2, elim
 
(h) 
T
max
 
(h) 
C
max
 
(ng/mL) 
Vd
obs
 
(mL/kg) 
Cl
obs
 
(mL/h/kg) 
MRT
last
 
(h) 
AUC
last
 
(h*ng/mL) 
AUC
last
/ 
Dose 
PLASMA 
Cisplatin 1.1 
mg/kg IV x1 
55.0 0.08 2,213.0 17,197.8 216.7 33.5 3,901.6 3,544.6 
Cisplatin 4.0 
mg/kg IV x1 
39.3 0.08 4,262.3 25,174.8 443.6 29.0 7,296.9 1,826.2 
NPs of Cisplatin –  
‘Low Load’ – 1.1 
mg/kg IV x 1 
13.7 0.08 5,077.4 3,346.4 169.2 12.2 6,451.3 5,864.8 
NPs of Cisplatin – 
‘High Load’ – 1.1 
mg/kg IV x 1 
19.7 0.08 7,088.1 3,274.7 115.3 9.7 9,377.4 8,524.9 
NPs of Cisplatin –  
‘High Load’ – 4 
mg/kg IV x 1 
17.0 0.08 22,733.5 2,190.3 89.5 9.4 44,199.1 11,049.8 
TUMOR 
Cisplatin 1.1 
mg/kg IV x1 
 
36.0 0.08 794.9 4,140.5 79.7 34.0 11,672.8 10,611.97 
Cisplatin 4.0 
mg/kg IV x1 
 
49.7 0.08 1,260.5 8,834.3 123.2 35.5 24,404.6 6,100.0 
NPs of Cisplatin –  
‘Low Load’ – 1.1 
mg/kg IV x 1 
80.3 0.08 452.7 3,422.2 29.5 43.0 23,314.3 21,194.8 
NPs of Cisplatin –  
‘High Load’ – 1.1 
mg/kg IV x 1 
32.0 1.0 1,038.7 1,181.6 25.6 31.7 36,885.9 33,532.6 
NPs of Cisplatin –  
‘High Load’ – 4 
mg/kg IV x 1 
37.6 6.0 5,924.4 1,099.7 20.3 32.2 155,529.6 38,882.4 
LIVER 
Cisplatin 1.1 
mg/kg IV x1 
 
101.2 0.08 881.1 2,413.3 16.5 44.8 31,945.3 29,041.2 
Cisplatin 4.0 
mg/kg IV x1 
 
196.1 0.08 1,443.7 4,173.6 14.8 45.0 78,885.0 19,721.3 
NPs of Cisplatin –  
‘Low Load’ – 1.1 
mg/kg IV x 1 
144.8 24.0 2,963.5 340.4 1.6 47.6 236,484.5 214,985.9 
NPs of Cisplatin –  
‘High Load’ – 1.1 
mg/kg IV x 1 
156.6 6.0 5,247.9 241.7 1.1 44.6 331,204.7 301,095.1 
NPs of Cisplatin –  
‘High Load’ – 4 
mg/kg IV x 1 
150.3 6.0 14,871.4 273.5 1.3 45.4 1,101,850.1 275,462.5 
SPLEEN         
Cisplatin 1.1 
mg/kg IV x1 
 
149.2 0.08 403.6 6,108.2 28.4 46.8 13,519.0 12,290.0 
Cisplatin 4.0 
mg/kg IV x1 
 
216.2 0.08 769.0 9,094.3 29.2 47.9 32,762.6 8,190.7 
NPs of Cisplatin –  
‘Low Load’ – 1.1 
mg/kg IV x 1 
131.0 24.0 1,311.0 761.5 4.0 47.0 103,724.6 94,295.1 
NPs of Cisplatin –  
‘High Load’ – 1.1 
mg/kg IV x 1 
350.6 6.0 2,049.1 565.1 1.2 46.6 163,567.2 148,697.5 
NPs of Cisplatin –  
‘High Load’ – 4 
mg/kg IV x 1 
92.8 24.0 7,332.0 469.6 3.5 44.5 567,283.3 141,820.8 
MUSCLE 
Cisplatin 1.1 
mg/kg IV x1 
 
81.5 0.08 324.0 14,447.9 122.9 41.9 5,226.2 4,751.1 
Cisplatin 4.0 
mg/kg IV x1 
 
61.1 0.08 634.9 15,626.3 177.3 44.2 12,842.3 3,210.6 
NPs of Cisplatin –  
‘Low Load’ – 1.1 
mg/kg IV x 1 
24.0 0.08 178.2 20,695.4 598.4 34.3 1,751.8 1,592.5 
NPs of Cisplatin –  
‘High Load’ – 1.1 
mg/kg IV x 1 
42.3 0.08 189.9 24,650.9 403.4 33.1 2,230.6 2,027.8 
NPs of Cisplatin –  
‘High Load’ – 4 
mg/kg IV x 1 
44.8 0.08 900.5 14,591.4 225.5 36.2 13,787.9 3,447.0 
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